Latest News
News Functions
Additional Functions
27 June 2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A.: Stefan Weber, buy
26 June 2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy
25 June 2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
18 June 2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy
17 June 2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A.: Dr. Ulrich Köstlin, buy
5 June 2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
22 May 2024
Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A.: Non-Exec. Director Luca Benatti, sell
13 May 2024
Newron Pharmaceuticals S.p.A.
Newron veröffentlicht zusätzliche Daten, welche die Wirksamkeit von Evenamide in der Zulassungsstudie 008A bei Schizophrenie-Patienten mit geringer Therapieansprache belegen
Newron Pharmaceuticals S.p.A.
Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
30 April 2024
Newron Pharmaceuticals S.p.A.
Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Newron Pharmaceuticals S.p.A.
Newron: Positive Topline-Ergebnisse der potenziell zulassungsrelevanten Phase-II/III-Studie 008A mit Evenamide in Schizophrenie-Patienten
17 April 2024
Newron Pharmaceuticals S.p.A.
Newron vermeldet die Resultate der Generalversammlung 2024
8 April 2024
Newron Pharmaceuticals S.p.A.
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
19 March 2024
Newron Pharmaceuticals S.p.A.
Newron presents 2023 financial results and provides 2024 outlook
Newron Pharmaceuticals S.p.A.
Newron gibt Geschäftsergebnisse 2023 und Ausblick 2024 bekannt
15 March 2024
Newron Pharmaceuticals S.p.A.
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Newron Pharmaceuticals S.p.A.
Newron gibt Vereinbarung mit der Europäischen Investitionsbank (EIB) über die Verschiebung der Rückzahlungstermine der anstehenden Tranchen seiner Finanzierungsvereinbarung von 2018 bekannt
14 March 2024
Newron Pharmaceuticals S.p.A.
Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
Newron Pharmaceuticals S.p.A.
Newron: Zeichnungsvereinbarung über bis zu 2,05 Millionen neu ausgegebene Aktien; Erlös von bis zu EUR 15,0 Mio.
12 January 2024
Newron Pharmaceuticals S.p.A.
4 January 2024
Newron Pharmaceuticals S.p.A.
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals S.p.A.
Newron berichtet positive Einjahres-Ergebnisse der Studie 014/15 mit Evenamide bei behandlungsresistenter Schizophrenie (TRS)
29 December 2023
Newron Pharmaceuticals S.p.A.
Newron schließt Rekrutierung von Schizophrenie-Patienten für potenziell zulassungsrelevante Studie 008A mit Evenamide ab
Newron Pharmaceuticals S.p.A.
Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
9 October 2023
Newron Pharmaceuticals S.p.A.
Newron TRS-Studie, 6-Monatsergebnisse: Evenamide verbessert Patienten in einem Ausmaß, dass sie nicht länger die Auswahlkriterien der Studie erfüllen
Newron Pharmaceuticals S.p.A.
Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
4 October 2023
Newron Pharmaceuticals S.p.A.
Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress